Literature DB >> 10742171

Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.

S Gonfloni1, A Weijland, J Kretzschmar, G Superti-Furga.   

Abstract

The catalytic activity of Src family tyrosine kinases is inhibited by intramolecular interactions between the regulatory SH3 and SH2 domains and the catalytic domain. In the inactive state, the critical alphaC-helix in the catalytic domain is positioned such that the formation of the Glu 310-Lys 295 salt bridge is precluded, Tyr 416 in the activation loop is unphosphorylated, and the SH2 and SH3 domains are unavailable for interactions with other proteins. We found that phosphorylation of the activation loop or mutation of the loop preceding the alphaC-helix activates Src and increases the accessibility of the SH3 domain for ligands. Interaction of the alphaC-helix with the activation loop is a central component of this regulatory system. Our data suggest a bidirectional regulation mechanism in which the regulatory domains inhibit Src activity, and Src activity controls the availability of the regulatory domains. By this mechanism, Src family kinases can be activated by proteins phosphorylating or changing the conformation of the catalytic domain. Once active, Src family kinases become less prone to regulation, implying a positive feedback loop on their activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10742171     DOI: 10.1038/74041

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  40 in total

1.  Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells.

Authors:  Q Kang; Y Cao; A Zolkiewska
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

2.  SRC-dependent outside-in signalling is a key step in the process of autoregulation of beta2 integrins in polymorphonuclear cells.

Authors:  Paola Piccardoni; Stefano Manarini; Lorenzo Federico; Zsuzsa Bagoly; Romina Pecce; Nicola Martelli; Antonio Piccoli; Licia Totani; Chiara Cerletti; Virgilio Evangelista
Journal:  Biochem J       Date:  2004-05-15       Impact factor: 3.857

Review 3.  Fyn in Neurodevelopment and Ischemic Brain Injury.

Authors:  Renatta Knox; Xiangning Jiang
Journal:  Dev Neurosci       Date:  2015-02-17       Impact factor: 2.984

4.  Deciphering the cross talk between hnRNP K and c-Src: the c-Src activation domain in hnRNP K is distinct from a second interaction site.

Authors:  Dörte Adolph; Nadine Flach; Katharina Mueller; Dirk H Ostareck; Antje Ostareck-Lederer
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

5.  Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Authors:  Mohammad Azam; Valentina Nardi; William C Shakespeare; Chester A Metcalf; Regine S Bohacek; Yihan Wang; Raji Sundaramoorthi; Piotr Sliz; Darren R Veach; William G Bornmann; Bayard Clarkson; David C Dalgarno; Tomi K Sawyer; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 6.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

7.  Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation.

Authors:  Adam H Courtney; Erik B Puffer; Jason K Pontrello; Zhi-Qiang Yang; Laura L Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

8.  An electrostatic network and long-range regulation of Src kinases.

Authors:  Elif Ozkirimli; Shalini S Yadav; W Todd Miller; Carol Beth Post
Journal:  Protein Sci       Date:  2008-08-07       Impact factor: 6.725

9.  The Tec family kinase Itk exists as a folded monomer in vivo.

Authors:  Qian Qi; Avery August
Journal:  J Biol Chem       Date:  2009-08-28       Impact factor: 5.157

10.  Cooperative activation of Src family kinases by SH3 and SH2 ligands.

Authors:  Shalini S Yadav; W Todd Miller
Journal:  Cancer Lett       Date:  2007-08-24       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.